Source disclosure: January 09, 2026
LIHIT LAB.,INC. [7975.T]
TOKYO — LIHIT LAB., INC. reported its third quarter earnings for the fiscal year ending February 2026 on January 9, 2026. The company's consolidated results for the period from March 1, 2025 to November 30, 2025 showed a decline across key performance indicators compared to the same period last year.
The company’s sales revenue decreased by 0.9% to ¥6,789 million from ¥6,850 million in the corresponding quarter of the previous fiscal year. Operating income fell sharply to ¥40 million, down 51.3%, while ordinary income dropped significantly to ¥28 million, marking an 87.8% decrease. These declines were reflected in the net income attributable to shareholders of the parent company, which plummeted to ¥215 million, representing a 28.9% reduction from ¥302 million in the prior-year period.
Regarding the financial position as of the end of the third quarter, Equity increased marginally to ¥10,767 million from ¥10,637 million, resulting in a modest rise in the equity ratio to 81.5% from 79.2%. No dividends have been paid out during this period, and no dividend payments are scheduled until further notice.
Looking ahead, LIHIT LAB. provided guidance for the full fiscal year ending February 2026. Sales revenue is expected to reach ¥9,200 million, showing a slight decrease of 0.2% from the previous year. Projected operating income is forecasted to be ¥80 million, indicating a significant drop of 55.2%, while ordinary income is anticipated to be ¥170 million, a reduction of 18.1%. Net income attributable to shareholders of the parent company is estimated at ¥120 million, reflecting a substantial decline of 70.8%.
These forecasts highlight continued challenges for the company amid changing market conditions. Notably, there have been adjustments in accounting policies due to changes in accounting standards, but no other material changes in accounting policies or estimates have occurred. The number of outstanding shares remained unchanged at 3,815,700, including treasury stocks amounting to 422,710 shares.
LIHIT LAB.'s management emphasized that these forward-looking statements are based on current information and reasonable assumptions but do not constitute guarantees of future performance. Actual outcomes may vary considerably due to various factors beyond the company's control. Investors are advised to review additional details regarding the assumptions underlying these projections and any cautionary notes provided in the supplementary materials accompanying the earnings release.
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms • Original filing